fragmentbas
method
drug
discoveri
increasingli
popular
provid
drug
lead
greater
ligand
effici
convent
highthroughput
screen
howev
establish
method
fragment
detect
address
central
question
fragmentbas
ligand
discoveri
primari
ligand
optim
extend
secondari
fragment
dynam
screen
method
solv
issu
use
protein
target
templat
ligand
assembl
thu
yield
highaffin
binder
lowaffin
fragment
review
summar
recent
work
dynam
screen
methodolog
result
develop
sever
highaffin
binder
variou
target
strength
limit
publish
approach
discuss
possibl
contribut
dynam
screen
methodolog
drug
discoveri
process
highlight
dynam
templateassist
strategi
fragmentbas
drug
discoveri
major
challeng
fragmentbas
drug
discoveri
identif
lowaffin
fragment
effici
biolog
activ
linkag
fragment
identifi
correspond
author
rademann
j
rademann
fmpberlind
pricewaterhousecoop
pharma
vision
path
take
http
see
front
matter
sinc
everincreas
number
protein
discov
postul
potenti
new
drug
target
demand
pharmaceut
industri
novel
drug
candid
chemic
biolog
field
chemic
tool
strongli
stimul
howev
actual
output
research
develop
r
describ
insuffici
proport
invest
made
exampl
overal
spend
biopharmaceut
r
reach
record
billion
north
america
year
us
food
drug
administr
fda
approv
new
molecular
entiti
nme
biolog
contrast
nme
approv
clinic
use
although
r
expenditur
less
half
amount
spent
discrep
term
compound
crisi
postul
result
ineffici
method
drug
discoveri
summar
innov
deficit
thu
appar
pharmaceut
industri
must
improv
r
product
use
new
technolog
develop
nme
concept
fragmentbas
drug
discoveri
small
beauti
fragmentbas
drug
discoveri
concept
develop
sinc
altern
convent
combinatori
chemistri
highthroughput
screen
ht
approach
figur
oppos
combinatori
chemistri
ht
use
larg
chemic
librari
requir
consider
effort
expens
librari
storag
qualiti
control
data
handl
fragmentbas
approach
requir
small
librari
often
member
start
point
conceptu
fragmentbas
drug
discoveri
base
consider
free
bind
energi
protein
ligand
result
contribut
molecular
compon
therefor
small
contribut
molecular
fragment
add
yield
highaffin
protein
ligand
figur
first
small
molecul
fragment
bind
protein
pocket
interest
identifi
start
fragment
chemic
modifi
gener
binder
higher
affin
subsequ
optim
lead
structur
figur
concept
becom
popular
two
main
reason
first
much
fewer
fragment
drugsiz
molecul
rough
estim
indic
approxim
fragment
heavi
atom
exist
exclud
structur
wherea
possibl
small
druglik
molecul
heavi
atom
comparison
approxim
molecul
synthes
date
thu
initi
screen
fragment
librari
expect
sampl
chemic
space
much
effici
tradit
approach
ever
could
second
reason
fragmentderiv
lead
structur
significantli
higher
ligand
effici
free
bind
energi
per
nonhydrogen
atom
ligand
molecul
discov
screen
larg
compound
librari
investig
known
natur
synthet
ligand
reveal
free
bind
energi
increas
proport
ligand
size
maximum
atom
maximum
averag
freeenergi
contribut
per
heavi
atom
kcalmol
molecul
larger
increas
ligand
effici
observ
observ
confirm
crucial
limit
molecular
size
effici
protein
ligand
therebi
support
prefer
fragment
hit
heavi
atom
per
molecul
typic
ht
hit
result
also
indic
easier
optim
hittolead
develop
fragment
hit
rel
ht
hit
weakli
bind
ligand
difficult
detect
gener
four
main
biophys
techniqu
use
task
nmr
spectroscopi
xray
crystallographi
surfac
plasmon
reson
isotherm
titrat
calorimetri
major
bottleneck
biophys
techniqu
high
protein
consumpt
need
expens
detect
equip
limit
throughput
moreov
method
solv
challeng
question
fragmentbas
discoveri
ie
two
lowaffin
binder
link
optim
yield
highaffin
binder
biophys
method
provid
inform
regard
optim
bioactiv
combin
fragment
address
problem
altern
socal
dynam
templateassist
strategi
propos
fragmentbas
drug
discoveri
discuss
method
use
target
protein
templat
select
andor
assembl
optim
fragment
combin
dynam
templateassist
approach
cover
review
common
chemic
reaction
revers
irrevers
enzymat
nonenzymat
exploit
detect
best
fragment
combin
first
step
direct
shift
chemic
equilibria
introduc
protein
realiz
dynam
combinatori
chemistri
dcc
figur
conceptu
extend
tether
dynam
combinatori
resolut
dcr
pseudodynam
combinatori
chemistri
pdcc
approach
second
subcategori
fragment
detect
compris
templateassist
strategi
targetguid
synthesi
tg
chemic
reaction
use
detect
catalyz
protein
substrat
activ
screen
sa
discuss
use
transfer
fragment
inform
substrat
nonsubstr
protein
ligand
final
dynam
ligat
screen
dl
use
classic
bioassay
fluorogen
substrat
competit
fluoresc
polar
fragment
detect
thu
use
ht
fragmentbas
drug
discoveri
signific
differ
dynam
templateassist
strategi
larg
determin
practic
use
drug
discoveri
one
major
criterion
amount
protein
requir
fragment
detect
strategi
dcc
pdcc
tg
requir
nearstoichiometr
stoichiometr
protein
quantiti
wherea
recent
develop
strategi
dcr
sa
dl
use
protein
templat
catalyt
amount
second
relev
criterion
detect
technolog
requir
dcc
tether
dcr
pdcc
tg
fragment
identif
reli
nmr
spectroscopi
chromatographi
xray
crystallographi
mass
fragmentbas
lead
discoveri
bind
small
molecular
fragment
protein
detect
lowaffin
fragment
link
provid
highaffin
ligand
howev
detect
linkag
fragment
difficult
task
physicochem
basi
fragmentbas
drug
discoveri
indic
free
bind
energi
ab
protein
ligand
result
addit
contribut
molecular
compon
b
bind
constant
k
ab
exponenti
function
bind
energi
c
dynam
strategi
fragmentbas
drug
discoveri
reactiv
fragment
incub
protein
form
specif
combin
fragment
protein
templat
facilit
fragment
detect
linkag
new
ligand
trend
biotechnolog
vol
spectrometri
recent
fragment
detect
consist
establish
highthroughput
methodolog
use
standard
microtit
plate
detect
fluoresc
absorpt
fluoresc
polar
dl
develop
final
method
describ
differ
significantli
scope
wherea
use
detect
wide
rang
protein
binder
other
specif
one
protein
class
protein
thu
aim
review
provid
orient
guid
potenti
user
dynam
templateassist
fragmentbas
methodolog
mixtur
compound
form
revers
chemic
equilibrium
interact
protein
shift
equilibrium
toward
best
bind
compon
expect
accord
law
mass
action
first
applic
principl
discoveri
protein
binder
report
huc
lehn
term
dcc
dcc
applic
demonstr
rtel
et
al
creat
imin
librari
condens
diamin
figur
deriv
tamiflu
known
inhibitor
neuraminidas
key
influenza
viru
enzym
differ
keton
detect
enzym
activ
imin
form
reduc
correspond
amin
addit
nacnbh
result
set
amin
analyz
hplc
highaffin
binder
neuraminidas
identifi
compar
hplc
chromatogram
reaction
contain
templat
control
howev
particular
applic
dcc
concept
rel
amplif
fragment
combin
correspond
bind
affin
compound
identifi
figur
exampl
compound
exhibit
greatest
amplif
potent
inhibitor
wherea
amplif
strongest
inhibitor
obtain
screen
threefold
less
number
possibl
explan
observ
particular
final
reduct
reaction
distort
result
two
way
amin
deriv
chemic
stabl
imin
expect
preferenti
form
irrespect
protein
templat
second
reduct
strongli
bind
imin
yield
amin
product
poorer
bind
properti
although
principl
dcc
applic
differ
type
protein
enzym
method
limit
nearstoichiometr
amount
protein
trend
biotechnolog
vol
requir
second
reaction
time
long
rang
day
week
third
larger
librari
difficult
screen
hplc
easili
use
separ
consider
larger
librari
addit
detect
preferenti
form
librari
member
via
reduct
correl
affin
origin
binder
thu
differ
amplif
affin
reduct
product
like
occur
tether
constitut
specif
form
dcc
introduc
sunesi
compani
wwwsunesiscom
approach
exploit
revers
disulfid
exchang
reaction
surfac
protein
disulfid
ligat
nativ
cystein
residu
use
altern
engin
proxim
site
interest
ad
crosslink
reaction
thiol
fragment
bind
tightli
screen
pocket
form
stabl
disulfid
cystein
residu
protein
thiolcontain
crosslink
key
advantag
tether
abil
focu
particular
region
templat
exampl
case
crosslink
deriv
aspart
bound
coval
enzym
crosslink
incub
disulfid
thiol
group
crosslink
interact
disulfid
exchang
reaction
disulfid
fit
preferenti
form
stabil
disulfideenzym
complex
could
detect
highresolut
mass
spectrometri
potent
inhibitor
could
obtain
figur
disadvantag
tether
approach
requir
nearstoichiometr
amount
templat
need
special
disulfid
librari
commerci
avail
fragment
detect
highresolut
mass
spectrometri
addit
tether
product
templatelink
disulfid
fragment
need
convert
chemic
stabl
ligand
need
retain
affin
disulfid
inform
obtain
nevertheless
tether
approach
enabl
sitedirect
screen
via
crosslink
contrast
dcr
pdcc
sa
broadli
applic
everi
type
protein
enzym
dynam
combinatori
resolut
dcr
pseudodynam
combinatori
chemistri
pdcc
dcr
pdcc
reli
concept
dcc
dynam
combinatori
librari
n
b
gener
incub
enzym
catalyz
irrevers
reaction
librari
member
n
b
c
nm
certain
degre
select
figur
select
process
perform
use
enzym
either
catalyz
bond
format
dcr
figur
cleavag
pdcc
figur
inspir
dynam
resolut
method
separ
racem
mixtur
group
introduc
concept
dcr
proof
principl
approach
provid
nitroaldol
reaction
socal
henri
reaction
bnitro
alcohol
revers
form
addit
nitroalkan
carbonyl
compound
addit
selector
case
lipas
psc
pseudomona
cepacia
librari
member
could
fit
activ
site
lipas
acyl
figur
subsequ
identifi
hnmr
exampl
dcr
dynam
nitroaldol
librari
form
henri
reaction
five
aldehyd
one
nitroalkan
compon
select
recognit
one
secondari
alcohol
form
selector
lipas
psc
led
enantioselect
format
two
ester
product
c
pdcc
librari
dipeptid
form
resinbound
activ
ester
left
dipeptid
could
cleav
nonselect
peptidas
pronas
dipeptid
bind
carbon
anhydras
protein
templat
partial
protect
hydrolysi
amplifi
iter
process
trend
biotechnolog
vol
pdcc
develop
kazlauska
group
replac
equilibrium
use
select
dcc
combin
irrevers
reaction
use
librari
format
enzymat
cleavag
librari
member
select
protein
templat
protect
betterbind
fragment
combin
enzymat
cleavag
wherea
unbound
compound
rapidli
remov
mixtur
concept
success
demonstr
carbon
anhydras
templat
use
synthet
dipeptid
librari
figur
incub
protein
templat
nonspecif
proteas
pronas
streptomyc
griseu
ad
hydrolyz
unbound
dipeptid
expect
cleavag
reaction
strongli
inhibit
best
binder
compar
weaker
binder
allow
detect
nmr
approach
amplif
correl
directli
bind
affin
compound
identifi
howev
one
major
disadvantag
difficulti
detect
best
fragment
combin
nmr
limit
possibl
librari
size
anoth
limit
restrict
applic
confin
chemic
librari
cleavag
reaction
establish
exampl
case
dcr
choic
selector
templat
confin
rel
enzym
lipas
prevent
broader
applic
particular
approach
drug
discoveri
howev
catalyt
amount
selector
protein
requir
constitut
clear
advantag
dcc
similar
dcr
pdcc
also
confin
specif
chemic
dipeptid
demonstr
ideal
establish
concept
howev
like
drug
lead
thu
summari
approach
although
conceptu
interest
less
like
wide
use
drug
lead
discoveri
logic
straightforward
extens
templateassist
shift
chemic
equilibria
direct
use
protein
target
either
templat
catalyst
irrevers
chemic
reaction
concept
term
tg
tg
protein
templat
bind
two
reagent
close
proxim
thu
acceler
chemic
reaction
usual
independ
actual
protein
function
sever
exampl
tg
demonstr
wide
use
reaction
tg
socal
situ
click
chemistri
click
reaction
azid
alkin
regioselect
yield
triazol
copper
catalysi
presenc
suitabl
protein
templat
howev
wellbound
azid
alkin
react
absenc
copper
salt
exampl
case
hiv
proteas
alkin
ic
mm
azid
ic
mm
incub
presenc
enzym
h
hplc
analysi
reveal
triazol
form
inhibitor
wildtyp
proteas
ic
nm
grow
import
triazol
drug
discoveri
situ
click
chemistri
could
becom
power
tool
lead
discoveri
principl
tg
suitabl
develop
highli
activ
molecul
broader
applic
howev
issu
address
templateassist
reaction
detect
desir
product
hplc
nmr
mass
spectrometri
need
present
rel
high
concentr
mm
second
need
nearstoichiometr
amount
templat
protein
limit
feasibl
tg
anticip
set
reaction
tg
particularli
suit
fulli
explor
research
carri
substrat
activ
screen
sa
sa
introduc
ellman
group
use
substrat
librari
screen
standard
enzym
assay
determin
best
bind
fragment
initi
method
demonstr
proteas
particular
applic
fluorophor
coupl
varieti
lowmolecularweight
fragment
result
socal
fluorogen
substrat
librari
member
screen
use
sever
proteas
cathepsin
shown
figur
identifi
best
proteas
substrat
via
cleavag
amid
bond
releas
fluoresc
dye
high
substrat
turnov
indic
high
affin
respect
substrat
fragment
case
cathepsin
nonpeptid
substrat
could
identifi
best
substrat
identifi
reaction
convert
inhibitor
introduc
aldehyd
cterminu
provid
nonpeptid
nanomolar
inhibitor
cathepsin
sa
also
use
identifi
protein
tyrosin
phosphatas
inhibitor
figur
substrat
librari
oaryl
phosphat
prepar
screen
mycobacterium
tuberculosi
protein
tyrosin
phosphatas
b
mptpb
secret
virul
factor
potenti
target
tuberculosi
tb
biphenyl
scaffold
could
identifi
potenti
lead
fragment
phosphat
group
molecul
replac
phosphat
mimet
follow
optim
potent
select
mptpb
inhibitor
obtain
figur
sever
molecul
act
therapeut
relev
enzym
alreadi
identifi
sa
strength
method
abil
effici
identifi
substrat
structur
bind
activ
site
use
protein
catalyt
amount
contribut
effici
howev
sa
requir
catalyt
function
enzymat
drug
target
proteas
protein
tyrosin
phosphatas
therefor
appli
gener
type
drug
target
approach
restrict
limit
avail
substrat
librari
commerci
avail
synthes
casebycas
basi
moreov
classic
rational
fragmentbas
drug
discoveri
ie
connect
sever
lowaffin
binder
specif
pocket
appli
sa
anoth
drawback
substrat
discov
convert
use
inhibitor
exampl
case
cathepsin
substrat
fluorophor
replac
aliphat
aldehyd
less
suitabl
drug
similarli
phosphatas
inhibitor
replac
phosphat
mimet
isothiazolidin
isoxazol
carboxyl
acid
result
advers
effect
lower
select
cell
permeabl
trend
biotechnolog
vol
dynam
ligat
screen
dl
consid
limit
differ
dynam
fragmentbas
method
drug
discoveri
dl
develop
approach
combin
dynam
targetassist
format
inhibitori
speci
detect
via
biochem
assay
exampl
enzym
reaction
use
amplifi
detect
fragment
thu
drastic
reduc
amount
protein
requir
allow
ht
figur
addit
use
chemic
reactiv
protein
ligand
bind
defin
pocket
protein
surfac
make
possibl
test
inhibitor
fragment
act
pocket
interest
dl
approach
first
demonstr
main
proteas
sar
coronaviru
sarscov
pro
protein
target
sitedirect
identif
inhibitori
fragment
activ
assay
sarscov
pro
first
develop
use
peptid
substrat
figur
enzymat
cleavag
peptid
substrat
releas
fluorophor
serv
indic
proteas
activ
chemic
reactiv
protein
ligand
peptid
aldehyd
incub
excess
nucleophil
fragment
presenc
enzym
follow
addit
fluorogen
substrat
rate
differ
substrat
turnov
quantifi
identifi
activ
inhibitori
fragment
sarscov
pro
one
fragment
identifi
show
consider
stronger
inhibit
presenc
peptid
aldehyd
peptid
aldehyd
inhibitor
alon
fragment
alon
show
signific
activ
sar
enzym
verifi
result
fragment
identifi
convert
chemic
synthesi
electrophil
shown
activ
inhibitor
sarscov
pro
use
new
chemic
reactiv
protein
ligand
thu
dl
approach
repeat
newli
identifi
electrophil
identifi
new
nucleophil
fragment
coval
linkag
new
electrophil
fragment
identifi
yield
activ
figur
overview
first
applic
substrat
activ
screen
sa
reaction
scheme
cathepsin
b
mycobacterium
tuberculosi
protein
tyrosin
phosphatas
b
mptpb
shown
trend
biotechnolog
figur
concept
dynam
ligat
screen
dl
illustr
develop
nonpeptid
sarscov
pro
inhibitor
substrat
shown
green
compet
peptid
aldehyd
inhibitor
orang
target
pocket
sarscov
main
proteas
gray
activ
amin
fragment
red
bind
pocket
lead
increas
inhibit
via
dynam
ligat
activ
protein
site
base
activ
amin
fragment
red
analog
electrophil
aldehyd
fragment
red
also
bind
synthes
use
dl
pocket
yield
activ
fragment
hit
final
hit
fragment
chemic
link
yield
nonpeptid
inhibitor
k
valu
mm
trend
biotechnolog
vol
nonpeptid
sarscov
pro
inhibitor
k
valu
mm
figur
conclus
dl
provid
sitedirect
detect
lowaffin
fragment
sensit
method
therefor
higher
convent
dynam
fragmentbas
approach
method
appli
highthroughput
format
addit
equip
besid
standard
microtit
plate
reader
need
importantli
dl
oper
iter
evolutionari
process
shown
succeed
transform
moder
activ
peptid
inhibitor
entir
nonpeptid
inhibitor
although
success
dl
demonstr
develop
proteas
inhibitor
date
dl
assay
could
easili
extend
proteas
enzym
class
well
type
proteinprotein
interact
standard
biochem
assay
includ
bind
assay
easili
adapt
particular
strategi
requir
methodolog
innov
drug
discoveri
process
requir
allevi
dwindl
success
current
drug
develop
effort
pharmaceut
industri
recent
advanc
dynam
fragmentbas
screen
method
potenti
contribut
significantli
process
combin
power
highthroughput
screen
advantag
fragmentderiv
hit
develop
dynam
ligat
screen
approach
fragmentbas
drug
discoveri
becom
competit
tradit
method
catalyt
amount
target
protein
requir
standard
ht
method
adapt
consid
recent
breakthrough
field
dynam
templateassist
strategi
face
next
challeng
must
demonstr
significantli
support
develop
approv
drug
firm
belief
success
applic
approach
yield
posit
result
near
futur
